In This Section

SU2C-Lustgarten Foundation Pancreatic Cancer Interception Research Team: Developing Novel Approaches to Treat and Evaluate Early Pancreatic Cancer

David P. Ryan, MD
Leader

David P. Ryan, MD

Massachusetts General Hospital Cancer Center

Alec C. Kimmelman, PhD
Co-leader

Alec C. Kimmelman, PhD

Perlmutter Cancer Center at NYU Langone

Research
The Research Team aims to intercept pancreatic ductal adenocarcinoma (PDAC) through a comprehensive approach that tests intensive preoperative treatments allowing more patients to achieve successful surgery and eradicate micrometastatic disease, and through the use of organoids to identify robust biomarkers of response to therapy. Through a clinical trial, the team is evaluating the therapeutic potential of addition of losartan, a drug that may enhance the efficacy of FOLFIRINOX. Furthermore, since preliminary data suggest that losartan therapy and radiation therapy alter the immune microenvironment, the team is also exploring the potential benefit of adding immunotherapy to the preoperative treatment regimen. The team has been exploring whether organoids grown from patients’ tumors prior to starting treatment can be used to predict patients’ response to FOLFIRINOX and other therapies.

Grant News

Research Team shows the feasibility of generating organoids within the perioperative recovery period of PDAC patients undergoing surgery